- Details
- Neal Shore and Alicia Morgans discuss the complex landscape of integrating radioligand therapies into the treatment paradigms for metastatic castration-resistant prostate cancer (mCRPC), and nuances around the multidisciplinary administration of radium-223. In evaluating how to best optimize patient care, they reflect on the currently approved life-prolonging therapies, novel mechanisms, and the d...
|
- Details
- Philip Koo and Alicia Morgans discuss the evolving role of nuclear medicine in the multidisciplinary care of patients receiving radium-223 for metastatic CRPC (Castration-Resistant Prostate Cancer). Dr. Koo advocates for the emergence of "nuclear oncology" as the fourth pillar in comprehensive cancer programs, emphasizing the need for enhanced communication and collaboration among medical oncologi...
|
- Details
- Brenda Martone and Alicia Morgans discuss the multidisciplinary approach used at Northwestern University's Robert H Lurie Comprehensive Cancer Center to ensure the safe and efficient administration of Radium-223 to patients with metastatic castration-resistant prostate cancer (mCRPC). They discuss the importance of treating bone health in these patients and ensuring they are on a proper bone-stren...
|
- Details
- Dr Phillip Koo joins Alicia Morgans in offering a nuclear oncology physician perspective on working together with oncologists, urologists, nurse practitioners, and other members of the treating community on patient selection for treatment with radium. Dr. Koo highlights the importance of identifying patients who have bone predominant disease, with no visceral metastatic disease, and consider radiu...
|
- Details
- In this conversation, Alicia Morgans and Tanya Dorff discuss selecting the appropriate patient for treatment with Radium-223. Prostate cancer is so dominated by bone metastases which significantly impact a patient's day-to-day functioning and quality of life. The phase 3 ALSYMPCA trial showed that radium-223 dichloride (radium-223), improved overall survival compared with placebo and was well tole...
|
- Details
- Fred Saad and Alicia Morgans discuss the management of patients who are receiving a bone supportive agent plus radium-223 in metastatic prostate cancer and the benefit in reduction of bone complications. Patients with prostate cancer who had bone fractures had a reduced survival rate. Doing everything clinicians can to reduce the risk of fractures can not only improve quality of life but may actua...
|
- Details
- Michael Morris joins Alicia Morgans in a discussion on combination therapies with Radium-223 for treating metastatic castration-resistant prostate cancer (mCRPC). Radium-223 is a bone-targeted alpha therapy and has been shown to prolong survival in patients with symptomatic mCRPC to the bone. Drs. Morris and Morgans highlight the DORA trial and focus on how combinations of treatment that either wo...
|
- Details
- In this conversation, Fred Saad and Alicia Morgans discuss the critical role of bone health in treating patients with metastatic castration-resistant prostate cancer (mCRPC), particularly when using radium. Dr. Saad highlights that while newer cancer treatments like enzalutamide and abiraterone have been effective, they shouldn't overshadow the importance of bone health. He points to the PEACE III...
|
- Details
- Brenda Martone and Alicia Morgans delve into the nuanced use of Radium for treating patients with metastatic CRPC (Castration-Resistant Prostate Cancer). Dr. Martone emphasizes that Radium is not just for alleviating bone pain but can also address other symptoms like fatigue and loss of appetite. She notes that the drug can be used at any point in the treatment continuum, depending on patient need...
|
- Details
- Michael Morris joins Alicia Morgans in a discussion on the sequencing of therapies in the context of radium for metastatic castration-resistant prostate cancer treatment. Their conversation focuses on thinking about prior exposure to radiopharmaceuticals when thinking about incorporating other radiopharmaceuticals into the treatment paradigm. As the conversation evolves, Drs. Morgans and Morris di...
|
